or Try an Advanced Search...

    Technical Analysis for TARA - ArTara Therapeutics, Inc.

    Grade Last Price % Change Price Change
    C 2.31 -0.43% -0.01
    TARA closed down 0.43 percent on Wednesday, November 20, 2024, on 16 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Down
    Historical TARA trend table...
    Date Alert Name Type % Chg
    1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
    NR7 Range Contraction 0.00%
    NR7-2 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Stochastic Reached Oversold Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    NR7 Range Contraction -0.43%
    Wide Bands Range Expansion -0.43%
    Fell Below 20 DMA Bearish 0.00%
    Older End-of-Day Signals for TARA ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 18 hours ago
    Possible Inside Day about 18 hours ago
    60 Minute Opening Range Breakdown about 20 hours ago
    Down 1% about 21 hours ago
    Possible NR7 1 day ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    TARA Chart by TradingView
    Basic chart:

    Profile

    ArTara Therapeutics, Inc., a clinical-stage company, develops product candidates for patients suffering from rare and specialty diseases. Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. The company's lead program is TARA-002, a cellular therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. ArTara Therapeutics, Inc. is based in New York, New York.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Rare Diseases Gastrointestinal Vitamins Chloride Lipid Liver Disease Hepatology Metabolic Disorders Choline Connective Tissue Cholinergics Treatment Of Rare Diseases

    Is TARA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 15 Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
    Nov 12 Protara Therapeutics GAAP EPS of -$0.50 beats by $0.02
    Nov 12 Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
    Nov 6 Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
    Oct 21 Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support
    Sep 9 Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
    Sep 9 Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
    Sep 3 Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    Aug 8 Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?
    Aug 6 Protara Therapeutics GAAP EPS of -$0.45
    See more TARA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.24
    52 Week Low 1.13
    Average Volume 171,373
    200-Day Moving Average 2.67
    50-Day Moving Average 2.08
    20-Day Moving Average 2.44
    10-Day Moving Average 2.49
    Average True Range 0.17
    RSI (14) 49.49
    ADX 36.08
    +DI 22.02
    -DI 19.30
    Chandelier Exit (Long, 3 ATRs) 2.27
    Chandelier Exit (Short, 3 ATRs) 2.29
    Upper Bollinger Bands 2.76
    Lower Bollinger Band 2.13
    Percent B (%b) 0.29
    BandWidth 25.74
    MACD Line 0.10
    MACD Signal Line 0.14
    MACD Histogram -0.0455
    Fundamentals Value
    Market Cap 26.25 Million
    Num Shares 11.4 Million
    EPS -6.13
    Price-to-Earnings (P/E) Ratio -0.38
    Price-to-Sales 0.00
    Price-to-Book 0.45
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.40
    Resistance 3 (R3) 2.40 2.37 2.38
    Resistance 2 (R2) 2.37 2.35 2.37 2.38
    Resistance 1 (R1) 2.34 2.33 2.35 2.34 2.37
    Pivot Point 2.31 2.31 2.32 2.31 2.31
    Support 1 (S1) 2.28 2.29 2.30 2.28 2.25
    Support 2 (S2) 2.25 2.27 2.25 2.24
    Support 3 (S3) 2.22 2.25 2.24
    Support 4 (S4) 2.22